更新了免疫参考页：结核病 (BCG)
Tuberculosis (TB) is a bacterial infection that predominantly manifests in the lungs but can spread to other areas of the body including the brain, bones, kidneys and lymph nodes. Whilst Australia has some of the lowest rates of TB in the world, it is estimated that globally one-quarter of the world’s population is infected.
Our reference page has recently been updated to include information on:
- the infection and what to look for
- epidemiology
- vaccination
- tuberculin skin testing.
要查看完整页面，请点击以下链接：
ATAGI 关于 5 至 11 岁儿童接种辉瑞 COVID-19 儿科疫苗加强剂量的建议
ATAGI have recommended COVID-19 booster doses for some groups of 5-11 year olds who have previously completed a primary course of COVID-19 vaccination. Eligible groups include those with severe immunocompromise, a disability with significant or complex health needs, or those with complex/multiple health conditions that increase the risk of severe COVID-19 disease.
Boosters in this age group can be administered 3 or more months after completing a primary course of COVID-19 vaccines. An interval of 3 months between COVID-19 infection and COVID vaccines is recommended.
There is currently not enough evidence to support booster doses for other groups of 5-11 year olds, however recommendations may change as more evidence emerges. All children in this age group are recommended to receive a primary course of COVID-19 vaccination.
To read the recommendations in full please follow the link below.
更新的免疫参考页 – 与疫苗接种相关的肩部损伤 (SIRVA)
Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare but serious complication following suspected inadvertent administration of a vaccine too high in the deltoid or into the shoulder joint. It can cause a local inflammatory response and potential trauma to local structures within the shoulder joint with symptoms lasting for weeks, months or even years.
我们的参考页面最近已更新为详细信息：
- symptoms/features of SIRVA
- impacts and implications
- diagnosis and treatment options
- how to prevent SIRVA
- where to report a case of SIRVA.
要查看完整页面，请点击以下链接：
微血管内皮细胞： Shoulder Injury Related to Vaccine Administration (SIRVA)
立即注册 CVU 2022！
不要忘记报名参加 10 月 28 日星期五举行的年度临床疫苗学更新 (CVU)！
我们的面对面活动将通过主题演讲和互动分组会议提供专业发展，以及与同行交流和交流的机会。
立即注册，不要错过这个机会，聆听顶尖专家介绍免疫领域的最新发展和趋势！
要查看该计划并注册，请点击下面的链接进入我们的活动页面：
MVEC：临床疫苗学更新 (CVU) 2022
更新的免疫参考页：接种 COVID-19 疫苗后的心肌炎和心包炎
MVEC’s myocarditis and pericarditis reference page has been updated following the recent changes to the guidance on myocarditis and pericarditis associated with COVID-19 vaccination.
This update is reflective of ATAGI’s recent advice which has identified that all of the COVID-19 vaccines available within Australia (including non-mRNA COVID-19 vaccines) carry a small increased risk of myocarditis or pericarditis occurring following vaccination.
要查看完整页面，请点击以下链接：
MVEC: Myocarditis and pericarditis following COVID-19 vaccines
Updated immunisation reference page - Pharmacist immunisers
Our pharmacist immuniser reference page has recently been updated to incorporate the expansion of the pharmacist immuniser program allowing accredited pharmacist providers to administer additional vaccines to more people.
Pharmacist immunisers that have completed a recognised ‘Immuniser program of study’, are now authorised to administer the following vaccines in Victoria:
- human papillomavirus (HPV) vaccines to those aged 12 years and older
- pneumococcal vaccines to people aged 50 years and older
- herpes zoster (shingles) vaccine to people aged 50 years and older
- monkeypox vaccines to patients recommended for vaccination aged five years and older.
In addition to this, pharmacist immunisers are now able to administer the diphtheria-tetanus-pertussis (dTpa) vaccine to anyone aged 12 years or older (previously only to those from 15 years of age).
要查看完整页面，请点击以下链接：
新的免疫参考页：体位性心动过速综合征 (POTS) 和免疫
Postural orthostatic tachycardia syndrome (POTS) is a condition that most commonly affects teens and young adults and involves a cluster of symptoms including increased heart rate (tachycardia), dizziness, weakness, vision changes, difficulty concentrating, sleep disturbances or nausea.
No link has been found between vaccination and POTS and a diagnosis of POTS is not a contraindication to receiving vaccinations. In fact, some cases of POTS are thought to occur following an acute infection, some of which are vaccine-preventable.
Vaccination is an important way to stay healthy and protected against disease. Any concerns an individual with POTS has regarding immunisation should be discussed with an individual’s treating healthcare practitioner.
Our new reference page outlines what POTS is and the implications of having POTS on immunisation.
For further information, click on the link below:
Postural orthostatic tachycardia syndrome (POTS) and immunisation
新的免疫参考页：脊髓灰质炎
脊髓灰质炎（脊髓灰质炎）是由 3 种脊髓灰质炎病毒（血清型 1、2 或 3）之一的胃肠道（肠道）感染引起的。脊髓灰质炎病毒是 RNA 肠道病毒，来自 小核糖核酸病毒科 家庭。
大约 70% 的脊髓灰质炎感染没有症状或表现为非特异性发热性疾病。据估计，在所有脊髓灰质炎病例中，弛缓性麻痹的发生率不到 1%。
我们的新参考页面详细介绍了传播途径、流行病学以及通过疫苗接种进行的预防。
要查看完整页面，请点击以下链接：
更新的免疫参考页：疫苗相关增强性疾病 (VAED)
疫苗相关增强性疾病 (VAED) 是一种罕见现象，在这种情况下，通常在未接种疫苗的人身上会出现（通常）更严重的感染临床表现，而在已接种疫苗的人身上会出现这种情况。
MVEC’s reference page on VAED has recently been updated. This resource outlines:
- what VAED is
- mechanisms for enhanced disease
- assessment and evaluation of VAED
要查看完整页面，请点击以下链接：
MVEC: Vaccine-associated enhanced disease (VAED)
CVU 10 月早鸟报名即将截止！
提前注册我们的年度临床疫苗学更新 (CVU) 10 月 28 日星期五 即将关门！
我们的面对面活动将通过主题演讲和互动分组会议提供专业发展，以及与同行交流和交流的机会。
立即注册，不要错过这个机会，聆听顶尖专家介绍免疫领域的最新发展和趋势。
要查看该计划并注册，请单击下面的链接进入我们的活动页面。